The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://carlysraz817660.diowebhost.com/93885593/retatrutide-vs-tirzepatide-a-comparative-analysis